We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Brigham investigators have created a ‘dual action’ treatment that combines immunotherapy with targeted drug delivery and shows promise in preclinical models of lung cancer.
